‘Inhalation Is A New Vector Of Growth’ For Amneal As Albuterol Goal Date Gets Closer
The Firm’s Generics Business Saw 14% YoY Growth In The First Half Of 2024
Amneal continues to grow its complex product portfolio, with multiple biosimilars and injectables launches coming in the near future, giving the firm confidence to raise its guidance.
